Collegium Pharmaceutical, Inc. COLL Segment — Product revenues, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s segment — product revenues, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s segment — product revenues, net?
- Collegium Pharmaceutical, Inc. (COLL) reported segment — product revenues, net of $193.52M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s segment — product revenues, net changed year-over-year?
- Collegium Pharmaceutical, Inc.'s segment — product revenues, net increased by 8.9% year-over-year, from $177.76M to $193.52M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s segment — product revenues, net?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s segment — product revenues, net has grown at a 18.9% compound annual growth rate (CAGR), from $463.93M to $780.57M.
- What does segment — product revenues, net mean?
- Represents the total revenue generated from the sale of pharmaceutical products after accounting for returns, rebates, and other sales deductions. This is the primary top-line metric for evaluating the market demand and commercial success of the company's drug portfolio.